Persons with dispensed medicines; age and sex
| Sex | Ages | Medicine group (ATC) | Periods | Persons with medicines, relative (%) |
|---|---|---|---|---|
| Total male and female | Total age | A02 Drugs for acid related disorders | 2022* | 12.48 |
| Total male and female | Total age | A02B Drugs for peptic ulcer and gord | 2022* | 12.48 |
| Total male and female | Total age | A02X Oth. drugs for acid related disord. | 2022* | 0.00 |
| Total male and female | Total age | A03 Drugs for funct.gastrointest.disord. | 2022* | 2.08 |
| Total male and female | Total age | A03A Drugs for functional bowel disord. | 2022* | 0.50 |
| Total male and female | Total age | A04 Antiemetics and antinauseants | 2022* | 0.74 |
| Total male and female | Total age | A04A Antiemetics and antinauseants | 2022* | 0.74 |
| Total male and female | Total age | A05C Bile therapy drugs and lipotropics | 2022* | 0.00 |
| Total male and female | Total age | A10 Drugs used in diabetes | 2022* | 4.85 |
| Total male and female | Total age | A10B Blood glucose lowering drugs, excl. | 2022* | 4.28 |
| Total male and female | Total age | A10X Other drugs used in diabetes | 2022* | 0.00 |
| Total male and female | Total age | A14 Anabolic agents for systemic use | 2022* | 0.00 |
| Total male and female | Total age | C01D Vasodilators used in card. diseases | 2022* | 1.40 |
| Total male and female | Total age | D01 Antifungals for dermatological use | 2022* | 4.48 |
| Total male and female | Total age | D01A Antifungals for topical use | 2022* | 4.11 |
| Total male and female | Total age | D01B Antifungals for systemic use | 2022* | 0.47 |
| Total male and female | Total age | D05A Antipsoriatics for topical use | 2022* | 0.49 |
| Total male and female | Total age | D05B Antipsoriatics for systemic use | 2022* | 0.02 |
| Total male and female | Total age | D06 Antibiotics.. for dermatological use | 2022* | 4.12 |
| Total male and female | Total age | D06A Antibiotics for topical use | 2022* | 3.45 |
| Total male and female | Total age | D06B Chemotherapeutics for topical use | 2022* | 0.73 |
| Total male and female | Total age | D10A Anti-acne preparations, topical use | 2022* | 0.87 |
| Total male and female | Total age | D10B Anti-acne preparations,systemic use | 2022* | 0.17 |
| Total male and female | Total age | G02B Contraceptives for topical use | 2022* | 0.09 |
| Total male and female | Total age | G03A Hormonal contraceptives system. use | 2022* | 1.67 |
| Total male and female | Total age | G04C Benign prostatic hypertrophy drugs | 2022* | 1.99 |
| Total male and female | Total age | H02 Corticosteroids for systemic use | 2022* | 4.71 |
| Total male and female | Total age | H02A Corticosteroids system.use, plain | 2022* | 4.67 |
| Total male and female | Total age | H02B Corticosteroids system.use, combi. | 2022* | 0.05 |
| Total male and female | Total age | J General antiinfectives for system.use | 2022* | 19.33 |
| Total male and female | Total age | J01 Antibacterials for systemic use | 2022* | 17.87 |
| Total male and female | Total age | J02 Antimycotics for systemic use | 2022* | 0.87 |
| Total male and female | Total age | J02A Antimycotics for systemic use | 2022* | 0.87 |
| Total male and female | Total age | J04A Drugs for treatment of tuberculosis | 2022* | 0.04 |
| Total male and female | Total age | J04B Drugs for treatment of lepra | 2022* | 0.01 |
| Total male and female | Total age | J05 Antivirals for systemic use | 2022* | 0.66 |
| Total male and female | Total age | M05 Drugs for treatment of bone diseases | 2022* | 1.23 |
| Total male and female | Total age | M09 Oth.drugs for musculo-skelet.disord. | 2022* | 0.00 |
| Total male and female | Total age | M09A Oth.disord.musculoskelet.syst.drugs | 2022* | 0.00 |
| Total male and female | Total age | N04 Anti-parkinson drugs | 2022* | 0.52 |
| Total male and female | Total age | N06D Anti-dementia drugs | 2022* | 0.11 |
| Total male and female | Total age | N07 Other nervous system drugs | 2022* | 0.69 |
| Total male and female | Total age | N07B Drugs used in addictive disorders | 2022* | 0.30 |
| Total male and female | Total age | N07X Other nervous system drugs | 2022* | 0.04 |
| Total male and female | Total age | R01B Nasal decongestants, systemic use | 2022* | 0.00 |
| Total male and female | Total age | R03 Drugs for obstruct. airway diseases | 2022* | 8.38 |
| Total male and female | Total age | R03B Oth.obstruct.airway dis.drugs/inhal | 2022* | 2.90 |
| Total male and female | 0 to 15 years | A02 Drugs for acid related disorders | 2022* | 0.50 |
| Total male and female | 0 to 15 years | A02B Drugs for peptic ulcer and gord | 2022* | 0.50 |
| Total male and female | 0 to 15 years | A02X Oth. drugs for acid related disord. | 2022* | 0.00 |
| Total male and female | 0 to 15 years | A03 Drugs for funct.gastrointest.disord. | 2022* | 0.32 |
| Total male and female | 0 to 15 years | A03A Drugs for functional bowel disord. | 2022* | 0.03 |
| Total male and female | 0 to 15 years | A04 Antiemetics and antinauseants | 2022* | 1.20 |
| Total male and female | 0 to 15 years | A04A Antiemetics and antinauseants | 2022* | 1.20 |
| Total male and female | 0 to 15 years | A05C Bile therapy drugs and lipotropics | 2022* | 0.00 |
| Total male and female | 0 to 15 years | A10 Drugs used in diabetes | 2022* | 0.15 |
| Total male and female | 0 to 15 years | A10B Blood glucose lowering drugs, excl. | 2022* | 0.01 |
| Total male and female | 0 to 15 years | A10X Other drugs used in diabetes | 2022* | 0.00 |
| Total male and female | 0 to 15 years | A14 Anabolic agents for systemic use | 2022* | 0.00 |
| Total male and female | 0 to 15 years | C01D Vasodilators used in card. diseases | 2022* | 0.00 |
| Total male and female | 0 to 15 years | D01 Antifungals for dermatological use | 2022* | 2.86 |
| Total male and female | 0 to 15 years | D01A Antifungals for topical use | 2022* | 2.80 |
| Total male and female | 0 to 15 years | D01B Antifungals for systemic use | 2022* | 0.08 |
| Total male and female | 0 to 15 years | D05A Antipsoriatics for topical use | 2022* | 0.08 |
| Total male and female | 0 to 15 years | D05B Antipsoriatics for systemic use | 2022* | 0.00 |
| Total male and female | 0 to 15 years | D06 Antibiotics.. for dermatological use | 2022* | 7.62 |
| Total male and female | 0 to 15 years | D06A Antibiotics for topical use | 2022* | 7.54 |
| Total male and female | 0 to 15 years | D06B Chemotherapeutics for topical use | 2022* | 0.10 |
| Total male and female | 0 to 15 years | D10A Anti-acne preparations, topical use | 2022* | 0.36 |
| Total male and female | 0 to 15 years | D10B Anti-acne preparations,systemic use | 2022* | 0.03 |
| Total male and female | 0 to 15 years | G02B Contraceptives for topical use | 2022* | 0.00 |
| Total male and female | 0 to 15 years | G03A Hormonal contraceptives system. use | 2022* | 0.57 |
| Total male and female | 0 to 15 years | G04C Benign prostatic hypertrophy drugs | 2022* | 0.00 |
| Total male and female | 0 to 15 years | H02 Corticosteroids for systemic use | 2022* | 0.82 |
| Total male and female | 0 to 15 years | H02A Corticosteroids system.use, plain | 2022* | 0.82 |
| Total male and female | 0 to 15 years | H02B Corticosteroids system.use, combi. | 2022* | 0.00 |
| Total male and female | 0 to 15 years | J General antiinfectives for system.use | 2022* | 14.48 |
| Total male and female | 0 to 15 years | J01 Antibacterials for systemic use | 2022* | 14.29 |
| Total male and female | 0 to 15 years | J02 Antimycotics for systemic use | 2022* | 0.09 |
| Total male and female | 0 to 15 years | J02A Antimycotics for systemic use | 2022* | 0.09 |
| Total male and female | 0 to 15 years | J04A Drugs for treatment of tuberculosis | 2022* | 0.01 |
| Total male and female | 0 to 15 years | J04B Drugs for treatment of lepra | 2022* | 0.00 |
| Total male and female | 0 to 15 years | J05 Antivirals for systemic use | 2022* | 0.06 |
| Total male and female | 0 to 15 years | M05 Drugs for treatment of bone diseases | 2022* | 0.00 |
| Total male and female | 0 to 15 years | M09 Oth.drugs for musculo-skelet.disord. | 2022* | 0.00 |
| Total male and female | 0 to 15 years | M09A Oth.disord.musculoskelet.syst.drugs | 2022* | 0.00 |
| Total male and female | 0 to 15 years | N04 Anti-parkinson drugs | 2022* | 0.00 |
| Total male and female | 0 to 15 years | N06D Anti-dementia drugs | 2022* | 0.00 |
| Total male and female | 0 to 15 years | N07 Other nervous system drugs | 2022* | 0.01 |
| Total male and female | 0 to 15 years | N07B Drugs used in addictive disorders | 2022* | 0.00 |
| Total male and female | 0 to 15 years | N07X Other nervous system drugs | 2022* | 0.00 |
| Total male and female | 0 to 15 years | R01B Nasal decongestants, systemic use | 2022* | 0.00 |
| Total male and female | 0 to 15 years | R03 Drugs for obstruct. airway diseases | 2022* | 6.56 |
| Total male and female | 0 to 15 years | R03B Oth.obstruct.airway dis.drugs/inhal | 2022* | 2.15 |
| Total male and female | 15 to 25 years | A02 Drugs for acid related disorders | 2022* | 1.08 |
| Total male and female | 15 to 25 years | A02B Drugs for peptic ulcer and gord | 2022* | 1.08 |
| Total male and female | 15 to 25 years | A02X Oth. drugs for acid related disord. | 2022* | 0.00 |
| Total male and female | 15 to 25 years | A03 Drugs for funct.gastrointest.disord. | 2022* | 1.49 |
| Total male and female | 15 to 25 years | A03A Drugs for functional bowel disord. | 2022* | 0.39 |
| Total male and female | 15 to 25 years | A04 Antiemetics and antinauseants | 2022* | 0.43 |
| Source: CBS. | ||||
Dataset is not available.
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Personal Records Database (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, age and sex.
Data available from: 2006
Status of the figures:
Figures for 2022 are provisional.
Changes as of December 20, 2023:
- Provisional figures for 2022 have been added, provisional figures of 2020 and 2021 have been made definite.
- Textual change: the description of drug group Y (Not filled in) has been replaced by Z (Not applicable). However, the underlying resources have remained the same. This category is assigned to products that do not have an ATC code according to the WHO ATC classification system.
When will new figures be published?
New figures will be published in the last quarter of 2024.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.